research Central nervous system demyelination associated with tofacitinib use in alopecia areata: A case report and literature review
Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.
Search
for
Sort by
Research
450-480 / 1000+ results research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
research Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
research Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Hair Growth Effect of DN106212 in C57BL/6 Mouse and Its Network Pharmacological Mechanism of Action
DN106212, an extract from a plant, is better at promoting hair growth than other tested substances by affecting hair growth factors and follicle development.
research Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
research Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research LB1011 Cost and access changes with TNFa inhibitor biosimilars entering the market
Biosimilars lower costs but don't significantly improve access.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
research Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
research Tanshinone, a Natural NADPH Oxidase Inhibitor, Mitigates Testosterone-Induced Hair Loss
Tanshinone compounds can help prevent hair loss caused by testosterone.
research Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
Baricitinib is the most effective treatment for alopecia areata.
research From joint pains to hair gains: baricitinib’s double duty for rheumatoid arthritis and alopecia areata
Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.
research Tratamiento con tofacitinib en adolescentes con alopecia areata
Tofacitinib treatment is used for teenagers with alopecia areata.
research Comparison of the pharmacoeconomic profiles of treatment regimens for field pattern actinic keratoses
Some blood pressure medications are linked to a higher risk of skin cancer.
research Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
research Tyrosine kinase inhibition and grey hair
Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
research BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
Setipiprant did not significantly improve hair growth in men with hair loss.
research Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata = Efficacy and safety of baricitinib treatment in alopecia areata:a retrospective analysis
Baricitinib is effective and safe for treating severe alopecia areata.
research 576 INTASYL PH-762: Intratumoral immunotherapy targeting PD-1
PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
research Arthritis drug spurs hair regrowth in alopecia patient
An arthritis drug helped a person with severe hair loss regrow their hair.
research BH14 Irish dermatologists’ experience with Janus kinase inhibitors in alopecia areata
Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
research Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.
research Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
research The role of oclacitinib in the management of ischaemic dermatopathy in four dogs
Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
research Androgen receptor modulators: a review of recent patents and reports (2012-2018)
New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
research Tofacitinib in the Management of Alopecia Universalis
Tofacitinib helped a woman regrow hair with no major side effects.
research Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario
Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.